Archive | August, 2016
PM 1a

Preparation and Distribution of Cannabis and Cannabis-Derived Dosage Formulations for Investigational and Therapeutic Use in the United States.

 2016 Aug 31;7:285. Thomas BF1, Pollard GT2. Author information Abstract Cannabis is classified as a schedule I controlled substance by the US Drug Enforcement Agency, meaning that it has no medicinal value. Production is legally restricted to a single supplier at the University of Mississippi, and distribution to researchers is tightly controlled. However, a majority of […]

PM 1a

A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis.

 2016 Aug 31;9:587-98. doi: 10.2147/JPR.S113138. eCollection 2016. Wilsey BL1, Deutsch R2, Samara E3, Marcotte TD2, Barnes AJ4, Huestis MA5, Le D1. Author information Abstract A randomized, placebo-controlled crossover trial utilizing vaporized cannabis containing placebo and 6.7% and 2.9% delta-9-tetrahydrocannabinol (THC) was performed in 42 subjects with central neuropathic pain related to spinal cord injury and disease. Subjects received two administrations of […]

PM 1a

From cannabis to cannabidiol to treat epilepsy, where are we?

2016 Aug 31. [Epub ahead of print] Lippiello P, Balestrini S, Leo A, Coppola A, Citraro R, Elia M, Russo E1, De Sarro G. Author information Abstract BACKGROUND: Several antiepileptic drugs (AEDs), about 25, are currently clinically available for the treatment of patients with epilepsy. Despite this armamentarium and the many recently introduced AEDs, no major advances have been achieved considering the […]

PM 1a

Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model.

2016 Aug 31;7(9). pii: E56. Gomis-González M1, Matute C2,3,4, Maldonado R5, Mato S6,7,8, Ozaita A9. Author information Abstract Fragile X syndrome (FXS) is the most common monogenetic cause of intellectual disability. The cognitive deficits in the mouse model for this disorder, the Fragile X Mental Retardation 1 (Fmr1) knockout (KO) mouse, have been restored by different pharmacological approaches, among […]

PM 1a

Cannabis and Pediatric Inflammatory Bowel Disease: Change Blossoms A Mile High.

2016 Aug 30. [Epub ahead of print]Hoffenberg EJ1, Newman H, Collins C, Leinwand K, Tarbell S. Author information Abstract The trend towards decriminalization of cannabis (marijuana) continues sweeping across the United States. Colorado has been a leader of legalization of medical and recreational cannabis use. The growing public interest in the medicinal properties of cannabis and its use by […]

PM 1a

Evaluation of Two Commercially Available Cannabidiol Formulations for Use in Electronic Cigarettes.

2016 Aug 29;7:279. doi: 10.3389/fphar.2016.00279. eCollection 2016. Peace MR1, Butler KE1, Wolf CE2, Poklis JL3, Poklis A4. Author information Abstract Since 24 states and the District of Columbia have legalized marijuana in some form, suppliers of legal marijuana have developed Cannabis sativa products for use in electronic cigarettes (e-cigarettes). Personal battery powered vaporizers, or e-cigarettes, were developed to deliver […]

PM 1a

GPR55-dependent stimulation of insulin secretion from isolated mouse and human islets of Langerhans.

2016 Aug 26. doi: 10.1111/dom.12780. [Epub ahead of print] Liu B1, Song S1, Maldonado IR1, Pingitore A1, Huang GC1, Baker D2, Jones PM1, Persaud SJ1. Author information Abstract AIMS: The novel cannabinoid receptor GPR55 is expressed by rodent islets and it has been implicated in β-cell function in response to a range of ligands. This study evaluated the effects of GPR55 ligands on intracellular […]


Evolution of the diacylglycerol lipases.

2016 Aug 26;64:85-97. doi: 10.1016/j.plipres.2016.08.004. [Epub ahead of print] Yuan D1, Wu Z2, Wang Y3. Author information Abstract Diacylglycerol lipases (DGLs) mainly catalyze “on-demand” biosynthesis of bioactive monoacylglycerols (MAGs) with different long fatty acyl chains, including 2-arachidonoylglycerol (2-AG), 2-linoleoylglycerol (2-LG), 2-oleoylglycerol (2-OG) and 2-palmitoylglycerol (2-PG). Enzymatic characterization of DGLs, their expression and distribution, and functional features has […]

American Diabetes Assoc Thumb

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

Khalid A. Jadoon, Stuart H. Ratcliffe, David A. Barrett, E. Louise Thomas, Colin Stott, Jimmy D. Bell, Saoirse E. O’Sullivan, Garry D. Tan Diabetes Care 2016 Aug; dc160650.  PreviousNext  Article Figures & Data Info & Metrics  PDF Abstract OBJECTIVE Cannabidiol (CBD) and Δ9-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes. RESEARCH […]

PM 1a

The gastrointestinal tract – a central organ of cannabinoid signaling in health and disease.

 2016 Aug 26. doi: 10.1111/nmo.12931. [Epub ahead of print]Hasenoehrl C1, Taschler U1, Storr M2,3, Schicho R1. Author information Abstract BACKGROUND: In ancient medicine, extracts of the marijuana plant Cannabis sativa were used against diseases of the gastrointestinal (GI) tract. Today, our knowledge of the ingredients of the Cannabis plant has remarkably advanced enabling us to use a variety […]